X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Relma-cel (relmacabtagene autoleucel) is based on the same chimeric antigen receptor (CAR) construct, currently beinf investigated in patients with moderately or severely refractory systemic lupus erythematosus.
Lead Product(s): Relmacabtagene Autoleucel
Therapeutic Area: Immunology Product Name: Relma-cel
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2023
Details:
Carteyva® (relmacabtagene autoleucel) is an autologous anti-CD19 CAR-T cell immunotherapy, which has been approved for relapsed or refractory large B-cell lymphoma and refractory follicular lymphoma.
Lead Product(s): Relmacabtagene Autoleucel
Therapeutic Area: Oncology Product Name: Carteyva
Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2023
Details:
JWATM214 is an autologous T-cell immunotherapy candidate drug targeting GPC-3 to delay T cell exhaustion, to achieve more durable and superior anti-tumor activity, potentially providing novel treatment for GPC-3-expressing advanced HCC patients.
Lead Product(s): JWATM214
Therapeutic Area: Oncology Product Name: JWATM214
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 28, 2023
Details:
The initial focus of the collaboration is 2seventy bio’s MAGE-A4 TCR program in solid tumors which is being developed as part of a collaboration with Regeneron. MAGE-A4 is a member of the MAGE family of cancer-testis antigens expressed in a number of solid tumor types.
Lead Product(s): TCR T-cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: 2Seventy Bio
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 27, 2022
Details:
Cohort B results showed that Carteyva® (relmacabtagene autoleucel) demonstrated very high rates of durable disease response (ORR)=100%, (CRR)=85.19% at month 3; ORR=92.58%, CRR=77.78% at month 6) and controllable CAR-T associated toxicities in patients with r/r FL.
Lead Product(s): Relmacabtagene Autoleucel
Therapeutic Area: Oncology Product Name: Carteyva
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
The approval of Carteyva (relmacabtagene autoleucel (relma-cel) injection), an autologous anti-CD19 CAR-T cell immunotherapy product is based on results of a RELIANCE study in treating pediatric and young adult patients with r/r B-ALL.
Lead Product(s): Relmacabtagene Autoleucel
Therapeutic Area: Oncology Product Name: Carteyva
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 20, 2022
Details:
Breakthrough Therapy Designation was supported by results from clinical study of Carteyva (relmacabtagene autoleucel) in relapsed or refractory MCL (r/r MCL), which aimed to assess the efficacy and safety of Carteyva® in adults with r/r MCL in China.
Lead Product(s): Relmacabtagene Autoleucel
Therapeutic Area: Oncology Product Name: Carteyva
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 03, 2022
Details:
Carteyva® (relmacabtagene autoleucel injection) also abbreviated as relma-cel,an autologous anti-CD19 CAR-T cell immunotherapy product, in the treatment of second-line large B-Cell lymphoma.
Lead Product(s): Relmacabtagene Autoleucel
Therapeutic Area: Oncology Product Name: Carteyva
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022
Details:
China NMPA has approved an application for registration of a new drug autoleucel relmacabtagen for the treatment of adult patients with recurrent or refractory large B-cell lymphoma (r / r HCL) after two or more lines of systemic therapy.
Lead Product(s): Autoleucel Relmacabtagen
Therapeutic Area: Oncology Product Name: JWCAR029
Highest Development Status: ApprovedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2021
Details:
The Partnership will support the clinical development and commercial manufacturing of leading CAR-T (Chimeric Antigen Receptor T-Cells) therapies in China, including JW Therapeutics’ lead product relmacabtagene autoleucel (“relma-cel”).
Lead Product(s): Relmacabtagene autoleucel
Therapeutic Area: Oncology Product Name: Relma-cel
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Recipient: Thermo Fisher Scientific
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 03, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
